Use of big data and machine learning algorithms to extract possible treatment targets in neurodevelopmental disorders.

Drug repurposing Genomics Machine learning Neurodevelopmental disorders Neuropsychiatric disorders Therapeutic targets

Journal

Pharmacology & therapeutics
ISSN: 1879-016X
Titre abrégé: Pharmacol Ther
Pays: England
ID NLM: 7905840

Informations de publication

Date de publication:
10 2023
Historique:
received: 13 04 2023
revised: 30 08 2023
accepted: 11 09 2023
medline: 2 10 2023
pubmed: 15 9 2023
entrez: 14 9 2023
Statut: ppublish

Résumé

Neurodevelopmental disorders (NDDs) impact multiple aspects of an individual's functioning, including social interactions, communication, and behaviors. The underlying biological mechanisms of NDDs are not yet fully understood, and pharmacological treatments have been limited in their effectiveness, in part due to the complex nature of these disorders and the heterogeneity of symptoms across individuals. Identifying genetic loci associated with NDDs can help in understanding biological mechanisms and potentially lead to the development of new treatments. However, the polygenic nature of these complex disorders has made identifying new treatment targets from genome-wide association studies (GWAS) challenging. Recent advances in the fields of big data and high-throughput tools have provided radically new insights into the underlying biological mechanism of NDDs. This paper reviews various big data approaches, including classical and more recent techniques like deep learning, which can identify potential treatment targets from GWAS and other omics data, with a particular emphasis on NDDs. We also emphasize the increasing importance of explainable and causal machine learning (ML) methods that can aid in identifying genes, molecular pathways, and more complex biological processes that may be future targets of intervention in these disorders. We conclude that these new developments in genetics and ML hold promise for advancing our understanding of NDDs and identifying novel treatment targets.

Identifiants

pubmed: 37708996
pii: S0163-7258(23)00194-8
doi: 10.1016/j.pharmthera.2023.108530
pii:
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108530

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that there are no conflicts of interest.

Auteurs

Muhammad Ammar Malik (MA)

Computational Biology Unit, Department of Informatics, University of Bergen, PO BOX 7803, 5020 Bergen, Norway.

Stephen V Faraone (SV)

Department of Psychiatry, Norton College of Medicine at SUNY Upstate Medical University, 13210, NY, USA.

Tom Michoel (T)

Computational Biology Unit, Department of Informatics, University of Bergen, PO BOX 7803, 5020 Bergen, Norway.

Jan Haavik (J)

Department of Biomedicine, University of Bergen, PO BOX 7804, 5020 Bergen, Norway; Bergen Center for Brain Plasticity, Division of Psychiatry, Haukeland University Hospital, PO BOX 1400, 5021 Bergen, Norway. Electronic address: Jan.Haavik@uib.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH